CA2137363A1 - Utilisation de glycoproteines de la membrane pellucide a des fins d'immunocontraception - Google Patents

Utilisation de glycoproteines de la membrane pellucide a des fins d'immunocontraception

Info

Publication number
CA2137363A1
CA2137363A1 CA 2137363 CA2137363A CA2137363A1 CA 2137363 A1 CA2137363 A1 CA 2137363A1 CA 2137363 CA2137363 CA 2137363 CA 2137363 A CA2137363 A CA 2137363A CA 2137363 A1 CA2137363 A1 CA 2137363A1
Authority
CA
Canada
Prior art keywords
zona pellucida
vaccine
immunocontraception
delivery system
liposome delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2137363
Other languages
English (en)
Other versions
CA2137363C (fr
Inventor
Robert Brown
Warwick Kimmins
Michael Mezei
Bill Pohajdak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovaccine Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2137363A1 publication Critical patent/CA2137363A1/fr
Application granted granted Critical
Publication of CA2137363C publication Critical patent/CA2137363C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002137363A 1992-06-05 1993-06-07 Utilisation de glycoproteines de la membrane pellucide a des fins d'immunocontraception Expired - Fee Related CA2137363C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89280792A 1992-06-05 1992-06-05
US892,807 1992-06-05
PCT/CA1993/000239 WO1993025231A1 (fr) 1992-06-05 1993-06-07 Utilisation de glycoproteines de la zone pellucide dans l'immunocontraception

Publications (2)

Publication Number Publication Date
CA2137363A1 true CA2137363A1 (fr) 1993-12-23
CA2137363C CA2137363C (fr) 1999-06-15

Family

ID=25400523

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137363A Expired - Fee Related CA2137363C (fr) 1992-06-05 1993-06-07 Utilisation de glycoproteines de la membrane pellucide a des fins d'immunocontraception

Country Status (3)

Country Link
AU (1) AU4303493A (fr)
CA (1) CA2137363C (fr)
WO (1) WO1993025231A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925142B2 (en) 2005-10-07 2018-03-27 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
US11077184B2 (en) 2011-10-06 2021-08-03 Immunovaccine Technologies Inc. Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response
US11235069B2 (en) 2007-09-27 2022-02-01 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US11717563B2 (en) 2008-06-05 2023-08-08 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140151A2 (fr) * 1998-12-22 2001-10-10 Dalhousie University Compositions et procedes pour reduire ou prevenir la fertilisation chez des poissons et des oiseaux
AU5909500A (en) * 1999-07-01 2001-01-22 University Of Georgia Research Foundation, Inc., The Method and composition for affecting reproductive systems
CA2378478A1 (fr) * 1999-07-01 2001-01-11 The University Of Georgia Research Foundation, Inc. Vaccin anti-fecondite contenant une proteine de membrane pellucide aviaire et procede d'utilisation
DE60117164T2 (de) 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
EP2344193B1 (fr) 2008-09-17 2013-10-02 The Government Of The United States Of America As Reresented By The Secretary Of The Department Of Health & Human Services Compositions immunocontraceptives recombinantes à base du virus de la rage et méthodes d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1504259A (en) * 1976-07-19 1978-03-15 Merck & Co Inc Immunological control of fertility
US4996297A (en) * 1987-10-07 1991-02-26 Zonagen, Inc. Recombinantly expressed rabbit zona pellucida polypeptides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925142B2 (en) 2005-10-07 2018-03-27 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
US11235069B2 (en) 2007-09-27 2022-02-01 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US11717563B2 (en) 2008-06-05 2023-08-08 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US11077184B2 (en) 2011-10-06 2021-08-03 Immunovaccine Technologies Inc. Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response

Also Published As

Publication number Publication date
AU4303493A (en) 1994-01-04
WO1993025231A1 (fr) 1993-12-23
CA2137363C (fr) 1999-06-15

Similar Documents

Publication Publication Date Title
CA2217178A1 (fr) Vaccins contenant une saponine ainsi qu'un sterol
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
CA2136429A1 (fr) Vaccins combines comprenant un antigene de surface anti-hepatite b et d'autres antigenes
CA2172507A1 (fr) Procedes et compositions de microencapsulation d'adjuvants
CA2123580A1 (fr) Antigene de proteine m hybride et porteur pour vaccin contre les streptocoques du groupe a
CA2183435A1 (fr) Vaccins contenant des vesicules lipidiques paucilamellaires comme adjuvants immunologiques
CA2132833A1 (fr) Vaccins contre l'hepatite renfermant du monophosphoryl-lipide a desacyle 3-o
MY111829A (en) Modified live brsv vaccine
CA2132547A1 (fr) Vaccins renfermant des vesicules d'agents tensioactifs non ioniques
CA2143823A1 (fr) Analogues synthetiques de peptides, modifies pour la reversion, l'inversion et la reversion-inversion
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
EP0017557A3 (fr) Particule de liposome contenant des sous-unités virales ou bactériennes antigéniques et procédé de préparation
AU4188100A (en) Dry formulation for transcutaneous immunization
CA2086094A1 (fr) Compositions de vaccin renfermant des liposomes
MX9803290A (es) Composiciones de la vacuna influenza.
CA2137363A1 (fr) Utilisation de glycoproteines de la membrane pellucide a des fins d'immunocontraception
EP0694309A3 (fr) Compositions vaccinales contenant des antigènes et des anticorps pour la prévention et l'inhibition d'infections induites par les staphylocoques
WO1999050303A3 (fr) Complexe d'alpha-2 macroglobuline modulateur de la reponse immunitaire
ES2156932T3 (es) Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas.
AU2458888A (en) Vaccine adjuvant
AU5441299A (en) Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
GEP20053446B (en) Adjuvant Combination Formulations
MX9604185A (es) Una vacuna que lleva sustancia auxiliar y que esta sustancialmente libre de albumina que no es del huesped.
ZA962616B (en) Vaccines
CA2128247A1 (fr) Vaccins bases sur la streptokinase

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed